Introduction
Psychiatric disease typically begins in childhood and adolescence, significantly impacting well-being and development [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1, Reference Copeland, Wolke, Shanahan and Costello2]. Childhood psychiatric problems are among the most common health issues, and their prevalence is increasing [Reference Copeland, Wolke, Shanahan and Costello2]. Attention-deficit hyperactivity disorder (ADHD) is one of the most widespread psychiatric diseases worldwide, especially in children and adolescents [Reference Polanczyk, Salum, Sugaya, Caye and Rohde3]. Psychiatric diseases often persist into adulthood, resulting in individual and collective social and economic burdens. This impact includes rising costs, education, welfare system, and administration of justice since it affects all aspects of life, such as school or work performance, relationships with family and friends, and community participation [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1]. According to the study of Doshi et al., total annual costs in the United States have been estimated to range from US$143 billion to $266 billion, including health care and educational services for children and loss of income and productivity for adults [Reference Sayal, Prasad, Daley, Ford and Coghill4, Reference Doshi, Hodgkins, Kahle, Sikirica, Cangelosi and Setyawan5]. Basic National Health Service costs for ADHD (excluding medication costs) in England and Wales have been estimated at £23 million for the initial specialist assessment and £14 million annually for follow-up care [Reference Sayal, Prasad, Daley, Ford and Coghill4, Reference King, Griffin, Hodges, Weatherly, Asseburg and Richardson6]. Shlander developed a model for ADHD drug costs in England and predicted in 2012 that costs would exceed £78 million [Reference Sayal, Prasad, Daley, Ford and Coghill4, Reference Schlander7].
In 2022, Barican et al. [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1] published a systematic review and meta-analysis that included 14 studies in 11 high-income countries with a pooled sample of 61,545 children aged 4–18 years. The most common psychiatric diseases were anxiety (prevalence 5.2%), attention-deficit/hyperactivity (3.7%), oppositional defiant (3.3%), substance use (2.3%), conduct (1.3%), and depressive (1.3%) disorders [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1]. Cénat et al. [Reference Cénat, Kokou-Kpolou, Blais-Rochette, Morse, Vandette and Dalexis8] compared ADHD among children and adolescents of different races. They included 23 studies, and the pooled prevalence rate of ADHD was 15.9% with the pooled sample size of n = 218,445 [Reference Cénat, Kokou-Kpolou, Blais-Rochette, Morse, Vandette and Dalexis8]. Shooshtari et al. conducted an updated systematic review in 2022 in Iran, including 34 original studies covering 33,621 Iranian children, adolescents, and adults [Reference Hakim Shooshtari, Shariati, Kamalzadeh, Naserbakht, Tayefi and Taban9, Reference Shooshtary, Chimeh, Najafi, Mohamadi, Yousefi-Nouraie and Rahimi-Mvaghar10]. The total prevalence of ADHD varies between 11% and 25.8% in preschool children, between 3.17% and 17.3% in school-aged children, and between 3.9% and 25.1% in adults [Reference Cénat, Kokou-Kpolou, Blais-Rochette, Morse, Vandette and Dalexis8]. Alhraiwil et al. [Reference Alhraiwil, Ali, Househ, Al-Shehri and El-Metwally11] investigated the prevalence of ADHD in different age categories (children, adolescents, students) among Arab countries and reported variability across studies, with ADHD prevalence ranging between 0.46 and 19.6%. Ayano et al. [Reference Ayano, Yohannes and Abraha12] evaluated ADHD prevalence in children and adolescents in Africa, reporting a pooled prevalence of ADHD 7.47%. Liu et al. estimated the prevalence of ADHD among Chinese children and adolescents [Reference Liu, Xu, Yan and Tong13]. The prevalence estimates of ADHD in Mainland China, Hong Kong, and Taiwan were 6.5%, 6.4%, and 4.2%, respectively, with a pooled estimate of 6.3% [Reference Liu, Xu, Yan and Tong13]. These prevalence estimates align with a systematic review and meta-analysis from 2017, where an overall pooled prevalence of ADHD among children and adolescents in China was 6.26% (95% CI: 5.36–7.22%) [Reference Wang, Liu, Li, Xu, Liu and Shi14]. Catalá-López et al. [Reference Catalá-López, Peiró, Ridao, Sanfélix-Gimeno, Gènova-Maleras and Catalá15] investigated the prevalence of ADHD among children and adolescents in Spain, with the overall pooled prevalence estimated at 6.8%. Willcut [Reference Willcutt16] conducted a comprehensive meta-analysis on the prevalence of DSM-IV ADHD. While individual studies reported varied prevalence estimates, the pooled results suggested that the prevalence of DSM-IV ADHD was similar, whether ADHD was defined by parent ratings, teacher ratings, or a best estimate diagnostic procedure in children and adolescents (5.9–7.1%) or by self-report measures in young adults (5.0%) [Reference Willcutt16]. Thomas et al. [Reference Thomas, Sanders, Doust, Beller and Glasziou17] conducted a systematic review and meta-analysis to estimate ADHD prevalence in children, with an overall pooled estimate of 7.2%. Systematic reviews by Polanczyk et al. (2015; [Reference Polanczyk, Salum, Sugaya, Caye and Rohde3]) reported a worldwide ADHD prevalence in children and adolescents of 3.4% and found that estimates of ADHD prevalence were significantly variable (2014; [Reference Polanczyk, Willcutt, Salum, Kieling and Rohde18]). In 2007, Polanczyk et al. published a systematic review and meta-regression analysis. The worldwide-pooled prevalence in subjects 18 years of age or younger from the general population or schools was 5.29%, and the prevalence estimate was associated with significant variability [Reference Polanczyk, de Lima, Horta, Biederman and Rohde19]. A few meta-analyses of epidemiological data on adult ADHD have been published; however, Simon et al. [Reference Simon, Czobor, Bálint, Mészáros and Bitter20] published the first meta-analysis in 2009, estimating the prevalence of ADHD in adulthood at 2.5% (95% CI 2.1–3.1). Dobrosavljevic et al. researched ADHD prevalence in older adults. They concluded that pooled prevalence estimates differed significantly across assessment methods: 2.18% (95% CI = 1.51, 3.16) based on research diagnosis via validated scales, 0.23% (0.12, 0.43) relying on clinical ADHD diagnosis, and 0.09% (0.06, 0.15) based on ADHD treatment rates [Reference Dobrosavljevic, Solares, Cortese, Andershed and Larsson21]. Song et al. [Reference Song, Zha, Yang, Zhang, Li and Rudan22] assessed the global prevalence of adult ADHD in the general population through a systematic review and meta-analysis. The prevalence of persistent adult ADHD was 2.58%, and that of symptomatic adult ADHD was 6.76% [Reference Song, Zha, Yang, Zhang, Li and Rudan22].
Worldwide, several systematic reviews and meta-analyses have been conducted to summarize the ADHD prevalence and analyze variation of prevalence estimates reported by individual studies. The variability in ADHD prevalence rates was mainly associated with the methodological characteristics of the studies, such as diagnostic criteria, source of information, and the impairment requirement for the diagnosis [Reference Polanczyk, Willcutt, Salum, Kieling and Rohde18, Reference Polanczyk, de Lima, Horta, Biederman and Rohde19, Reference Fayyad, Sampson, Hwang, Adamowski, Aguilar-Gaxiola and Al-Hamzawi23]. Geographical location was not a primary factor associated with the variability of prevalence estimates [Reference Willcutt16, Reference Polanczyk, Willcutt, Salum, Kieling and Rohde18, Reference Polanczyk, de Lima, Horta, Biederman and Rohde19]. Variations in prevalence were also confirmed in the World Mental Health Surveys, where adult ADHD prevalence averaged 2.8% across surveys and was higher in high (3.6%)- and upper-middle (3.0%)- than low-/lower-middle (1.4%)-income countries [Reference Song, Zha, Yang, Zhang, Li and Rudan22].
Accurate prevalence estimates of psychiatric diseases in children and adolescents are crucial to evaluate and properly address burdens, as these disorders often persist into adulthood and can lead to the loss of human potential [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1, Reference Polanczyk, Salum, Sugaya, Caye and Rohde3]. Policymakers require prevalence data from multiple high-quality epidemiological studies using current or recent diagnostic standards with rigorous diagnostic measures [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1]. Systematic review and meta-analysis methods are optimal choices for providing high-quality, relevant, accessible, and up-to-date information that is crucial for policymakers [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1, 24]. In the context of the previous limitation in the meta-analyses and systematic reviews mentioned above and the high ADHD disease burden worldwide, the primary rationale for this review is to obtain the latest data on ADHD prevalence and differences in prevalence among different study types. These data would help calculate the disease burden and help policymakers and clinicians better plan resources for ADHD management.
Methods
We followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [Reference Liberati, Altman, Tetzlaff, Mulrow, Gøtzsche and Ioannidis25]. The protocol for this systematic review was registered in PROSPERO (CRD42020200220).
Literature search
We conducted a search on PubMed/MEDLINE until 2024/1/02 for articles in all languages using search terms related to “Attention-Deficit/Hyperactivity Disorder” and “Epidemiology,” “Prevalence,” and “Point Estimate.” The detailed search strategy is available in the Supplementary material. No restrictions were applied concerning language or type of document; we included full-text published articles or conference proceedings.
Selection criteria
We included observational cohort studies (retrospective, prospective, register-based population studies); cross-sectional studies; and clinical studies with participants from the general population (e.g., community samples, population-based registries, etc.) diagnosed with ADHD using either: a) clinical diagnosis according to the International Classification of Diseases (ICD) or DSM criteria reported in registers/medical files or self-reported medical history; or b) research diagnosis of ADHD, that is, meeting the threshold/cut-off levels on an ADHD-validated scales based on the DSM or ICD. We considered studies with data on ADHD prevalence in those populations.
We excluded articles that were not in English (515 articles). Additionally, we excluded studies conducted in nonrepresentative samples of the general population (e.g., only boys/men, siblings) or in selected areas (e.g., only rural/urban areas with small samples). Studies not focusing on the prevalence of ADHD per se, despite providing some data about it, as well as those presenting the lifetime prevalence of ADHD and including only patients with ADHD receiving pharmacological treatment, were also excluded.
Data extraction
References to studies identified in electronic searches were managed in MS Excel®. Titles/abstracts were screened by two authors (SP, KŠ), and full-text articles were independently screened by two authors ( SP and KŠ). Senior authors (MŠ, IL) were consulted to reach a consensus when needed. Two authors ( SP and KŠ) independently extracted data. The following data were extracted: first author and year of publication; year of data collection (if applicable); country; age category; number of individuals with ADHD; sample size; and prevalence assessment method group (one-stage clinical studies, two-stage clinical studies, surveys, and registry studies on medical records data). Age categories were defined as preschool children (below 6 years), school children (6–12 years), adolescents (12–18 years), and adults (above 18 years). Combinations of age categories were also included. A margin of 6 years was allowed for the preschool and school children categories, while an age interval of 11–13 years was allowed for the categories school children and adolescents. For the adult category, the age range had to be over two decades. Prevalence estimates from the same study based on different countries, age groups, or time frames were considered separate datasets. In case of overlapping study samples, the study that was published earlier and/or the study that was the most pertinent to our criteria was included. If the prevalence estimate was not reported or could not be calculated based on data from the paper, a study was excluded from the systematic review.
Data synthesis
Data synthesis was performed separately for each of the four prevalence assessment method groups. As a rule, three or more studies should be available for each subgroup. The meta-analysis of prevalence data and forest plot construction was performed in an R statistical environment. Age categories were used as subgroups in the meta-analysis (version 4.3.1), utilizing the function metaprop within the “meta” package. Due to the expected high heterogeneity, the random-effect model was applied and the restricted maximum-likelihood estimator was used for calculating between-study variance. The overall prevalence was calculated using the logit transformation. The confidence interval of the overall prevalence estimate was calculated based on Hartung-Knapp adjustment. Confidence intervals of prevalence for individual studies were calculated based on exact binominal intervals.
Results
In total, 8,332 records were retrieved and 508 studies were subjected to full evaluation. A total of 117 studies covering children, adolescents, and adults were included in the systematic review (Figure 1). Then, 103 studies representing 159 independent samples were included in the meta-analysis. The majority of these studies (116 studies) were conducted in different countries worldwide, while one study was conducted in 10 countries in the Americas, Europe, and the Middle East [Reference Fayyad, Sampson, Hwang, Adamowski, Aguilar-Gaxiola and Al-Hamzawi23]. Of the 117 included studies, 26 studies were conducted in Asia (6 in China, 7 in India, 4 in Turkey); 32 in Europe, 26 studies in North America (19 of them in the United States); 3 studies in South America; 10 studies in Africa; 12 in the Middle East; and 3 in Oceania.
PRISMA flowchart.
We summarized descriptive data for studies included in the systematic review in Tables 1–3.
Descriptive data for studies included in the systematic review – register studies and surveys
ICD-10, The International Classification of Diseases 10th Revision; ICD-10-GM, German modification of the International Classification of Diseases 10th Revision; ICD-9, The International Classification of Diseases 9th Revision; ICD-9-CM, The International Classification of Diseases 9th Revision Clinical Modification; DSM-4, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth dition; DSM-5: Diagnostic and Statistical Manual of Mental Disord ers, fifth edition; ICD-10-CA: International Classification of Diseases, 10th Revision, with Canadian Enhancements; F, females; M, males.
The included studies focused mostly on the population of preschool children, children in elementary school, adolescents, and young adults.
Diagnoses in these studies were determined through the analysis of electronic health records, population-based and administrative data, and/or health insurance data (register studies). They provided information through surveys (survey studies) and interviews with children, parents/guardians and/or teachers, using measures that included DSM and/or ICD diagnostic criteria (one-stage and two-stage clinical studies).
Overall prevalence of ADHD
The prevalence estimates of ADHD reported in the included studies varied substantially and offered a range of heterogeneous data. Heterogeneity was attributed mostly to the studies’ methodological characteristics and age categories. Subgroup analysis showed that the prevalence estimates differed significantly across different age categories, except for the meta-analysis done for one-stage clinical studies. Furthermore, the remaining heterogeneity within subgroups remained high, above 90% in almost all age subgroups and all study types.
Prevalence of ADHD in register studies and surveys
In total, 42 studies assessed the prevalence of ADHD by analyzing different databases or conducting a health survey. These studies are presented in Table 1.
The primary data source for the 32 studies was a review of electronic health and/or administrative records for a cohort of patients. Then, 13 studies were conducted in North America, 14 in Europe, 3 in Asia, and 2 in the Middle East.
The majority of the studies included children and/or adolescents. Twelve studies also included young adults and/or adults. In the study of Bachmann et al. [Reference Bachmann, Philipsen and Hoffmann27], the frequency of ADHD diagnosis in the age range of 18–69 years was 0.2% (M: 0.3%; F: 0.2%) in 2009 and 0.4% (M: 0.5%; F: 0.3%) in 2014. In the study of Burd et al. [Reference Burd, Klug, Coumbe and Kerbeshian31], after 18 years of age, ADHD was diagnosed in 2% of the population. Hauck et al. [Reference Hauck, Lau, Wing, Kurdyak and Tu37] concluded that the overall prevalence of ADHD was 5.4%, with a higher prevalence in males but in not females, in older cohorts, although the reasons for the higher prevalence in older age categories were unclear. In the study of Chung et al. [Reference Chung, Jiang, Paksarian, Nikolaidis, Castellanos and Merikangas33] 1.12% adult patients received diagnoses of ADHD [Reference Chung, Jiang, Paksarian, Nikolaidis, Castellanos and Merikangas33]. Prevalence increased from 0.43% in 2007 to 0.96% in 2016. Among children aged 5–11 years, the prevalence increased from 2.96% in 2007 to 3.74% in 2016 [Reference Chung, Jiang, Paksarian, Nikolaidis, Castellanos and Merikangas33]. Most recent studies focused on the increase in the prevalence of patients diagnosed with ADHD and on the other hand underdiagnosis and undertreatment of ADHD. Giacobini et al. [Reference Giacobini, Ahnemark, Medin, Freilich, Andersson and Ma40] reported the annual prevalence of diagnosed ADHD in Sweden as 1.1 per 1,000 persons in 2006, which increased to 4.8 per 1,000 persons in 2011 (in all ages). They also concluded that the mean age of patients diagnosed with ADHD increased between 2006 and 2011, with a slight increase in the mean age of new diagnoses (21.2 in 2007 and 22.3 in 2011) [Reference Giacobini, Ahnemark, Medin, Freilich, Andersson and Ma40]. In the cohort study by McKechnie et al. [Reference McKechnie, O’Nions, Dunsmuir and Petersen47], the prevalence of ADHD diagnoses is highest among children. The overall proportion of ADHD diagnoses in male children aged 3–17 years was 175 per 10 000 (95% CI 174–177), or 1.8%; in female children aged 3–17 years, it was 37.7 per 10 000 (95% CI 37.1–38.3), or 0.4%. For male adults aged 18–99 years, the overall proportion was 28.8 per 10 000 (95% CI 28.6–29.0), or 0.3%; for female adults aged 18–99 years, it was 7.2 per 10 000 (95% CI 7.1–7.3), or 0.07% [Reference McKechnie, O’Nions, Dunsmuir and Petersen47]. Proportionally, rates increased among adults from 2000 to 2018. However, the authors found evidence of increases in the proportion of people with ADHD diagnoses between 2000 and 2018 [Reference McKechnie, O’Nions, Dunsmuir and Petersen47]. Ramos-Quiroga et al. [Reference Ramos-Quiroga, Richarte, Soto, Targhetta, Ward and Perulero50] reported that ADHD continues to be underdiagnosed and undertreated, particularly in female adults. The prevalence of ADHD in children was estimated at 4.9%, whereas that in adults was estimated at 0.1%.
In the study of Holden et al. [Reference Holden, Jenkins-Jones, Poole, Morgan, Coghill and Currie42], diagnostic criteria were not explicitly defined; McKechnie et al. [Reference McKechnie, O’Nions, Dunsmuir and Petersen47] used the Read code system. DSM diagnostic criteria were used in the study by Brook et al. [Reference Brook and Boaz29] Fast et al. [Reference Fast, Wentz, Roswall, Strandberg, Bergman and Dahlgren38], Habdank-Kolaczkowski [Reference Habdank-Kolaczkowski, Akahara, Ishola, Salawu, Augustine and Ezeamii41], and Davidovitch et al. [Reference Davidovitch, Koren, Fund, Shrem and Porath34]. In other studies, ICD-9 and/or ICD-10 criteria were used.
Eight survey studies were conducted in North America (Canada and the United States). Five studies assessed ADHD in children and adolescents (3–17 years old). In these studies, the person most knowledgeable about the child, parent, or guardian answered questions about the presence of a child’s psychiatric diagnosis of ADHD, confirmed by a doctor or other healthcare provider. Children and/or adolescents were subjects in eight studies. Ten Have et al. [Reference Ten Have, Tuithof, van Dorsselaer, Schouten, Luik and de Graaf63] and Hesson et al. [Reference Hesson and Fowler60] examined the prevalence of ADHD in adults. In both studies, ADHD prevalence was higher in men than in women (3.7% vs. 2.7% in women and 3.2% overall [Reference Ten Have, Tuithof, van Dorsselaer, Schouten, Luik and de Graaf63]; n = 287, 58.8% vs. n = 201, 41.2% in women [Reference Hesson and Fowler60]). Diagnostic criteria were not explicitly defined in two studies – Parasurman et al. [Reference Parasuraman, Ghandour and Kogan61] and Visser et al. [Reference Visser, Danielson, Bitsko, Holbrook, Kogan and Ghandour64]. In other studies, the DSM criteria (or in combination with ICD criteria) were used.
Prevalence of ADHD in one-stage clinical studies
Twenty-five studies provided data on ADHD prevalence by one-stage clinical studies. These studies are presented in Table 2. Data collection tools used were: The Mini International Neuropsychiatric Interview (MINI), Development and Well-Being Assessment, Diagnostic Interview Schedule for Children (DISC), Diagnostic Interview for Children and Adolescents (DICA), INCLEN Diagnostic Tool for Attention-Deficit Hyperactive Disorder, DSM-IV questionnaire, The Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS), ADHD Rating Scale, Child Behavior Checklist, Teacher’s Report Form, Youth Self-Report, Peer-Relations Questionnaire, and Revised Behavior Problem Checklist.
Descriptive data for studies included in the systematic review – one-stage clinical studies
DSM-III, The Diagnostic and Statistical Manual of Mental Disorders, Third Edition; DSM-III-R, The Diagnostic and Statistical Manual of Mental Disorders, Revision, Third Edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders Text Revision Fourth Edition; DSM-IV, The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-5, The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ICD-9, The International Classification of Diseases 9th Revision; ICD-10, The International Classification of Diseases 10th Revision; DISC-C, Diagnostic Interview Schedule for Children, Child Version; INDT-ADHD, INCLEN Diagnostic Tool for Attention-Deficit Hyperactivity Disorder; DICA-R, Diagnostic Interview for Children and Adolescents; DSM-IV questionnaire, The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition questionnaire; DAWBA, Development and Well-Being Assessment; K-SADS-PL The Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version; K-SADS, The Kiddie Schedule for Affective Disorders and Schizophrenia; ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale IV, teacher and parent forms; CBCL, Child Behavior Checklist; TRF, Teacher’s Report Form; DISC-IV, Diagnostic Interview Schedule for Children, Version IV; DISC, Diagnostic Interview Schedule for Children; YSR, Youth Self-Report; PRQ, Peer-Relations Questionnaire; RBPC, Revised Behavior Problem Checklist.
Three studies were conducted in North America, three in South America, four in Europe, seven in Asia, two in Africa, three in Oceania, and three in the Middle East.
Gomes et al. [Reference Gomes, Soares, Kieling, Rohde and Gonçalves79] assessed the prevalence of ADHD in young adults, other studies evaluated ADHD prevalence in children and/or adolescents (Cuffe et al. [Reference Cuffe, McKeown, Jackson, Addy, Abramson and Garrison72] and Moffitt et al. [Reference Moffitt, Houts, Asherson, Belsky, Corcoran and Hammerle85] included also adults). Gomes et al. [Reference Gomes, Soares, Kieling, Rohde and Gonçalves79] used data from the 1993 Pelotas Birth Cohort (Brazil) and assessed the prevalence of psychiatric diseases at 22 years using the MINI. The ADHD prevalence was 4.5% (M: 4.1%, F: 4.8%) [Reference Gomes, Soares, Kieling, Rohde and Gonçalves79]. The weighted prevalence of DSM-III-R ADHD in the study of Cuffe et al. [Reference Cuffe, McKeown, Jackson, Addy, Abramson and Garrison72] was 1.51% (males: 2.62%, females: 0.54%), with significant association for gender (male). Moffitt et al. [Reference Moffitt, Houts, Asherson, Belsky, Corcoran and Hammerle85] reported 3% prevalence in the adult-ADHD group and gender balance.
Ashenafi et al. did not explicitly defined diagnostic criteria; however, DICA was used (structured interview for school-age children, based on the DSM criteria [Reference Ashenafi, Kebede, Desta and Alem69]). In other studies, the DSM criteria (or in combination with ICD criteria) were used.
Prevalence of ADHD in two-stage clinical studies
Fifty studies provided data on ADHD prevalence through two-stage clinical studies. These studies are presented in Table 3. In the first stage, a questionnaire screening phase was conducted, followed by a diagnostic interview.
Descriptive data for studies included in the systematic review - two-stage clinical studies
DSM, The Diagnostic and Statistical Manual of Mental Disorders; DSM-III-R, The Diagnostic and Statistical Manual of Mental Disorders, Revision, Third Edition; DSM-IV, The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-5, The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders Text Revision Fourth Edition; ICD-9, The International Classification of Diseases 9th Revision; ICD-10, The International Classification of Diseases 10th Revision; CAARS, The Conners’ Adult ADHD Rating Scale; CBRS, The Conner’s index questionnaire; YSR, Youth Self-Report; SCOFF, a five-question screening tool designed to clarify suspicion that an eating disorder might exist rather than to make a diagnosis; CDI-MD, Childrens’ Diagnostic Interview for Mental Disorders; ASRS, The World Health Organization Adult ADHD Self-Report Scale; CBCL, The Achenbach’s Child Behavior Checklist; MINI, Mini International Neuropsychiatric Interview; SDQ, Strengths and Difficulties Questionnaire; DAWBA, Development and Well-Being Assessment; BASC, Behavior Assessment System for Children Colombian version; CBCL, Child Behavior Checklist; K-SADS-PL, Schedule for Affective Disorders and Schizophrenia for School-Aged Children; Present and Lifetime version; C-GAS, The Children’s Global Assessment Scale; WISCIII, The Wechsler Intelligence Scale for Children; ASSQ, The Autism Spectrum Disorder Screening Questionnaire; PDD, a checklist containing the diagnostic criteria for Pervasive Developmental Disorders; CASS:S, Conners-Wells’ Adolescent Self-Report Scale-Short form; RA2, the Rutter Parent Questionnaire; RB2, The Rutter Teacher Questionnaire; CDI, The Children’s Depression Inventory; CDI, The Children’s Depression Inventory; IWI, The semi-structured Isle of Wight Interview; DISC-C, The Diagnostic Interview Schedule for Children, child version; SWAN, The Strengths and Weaknesses of ADHD-Symptoms and Normal Behavior; TRF, Teacher’s Report Form; ACDS, Adult ADHD Clinical Diagnostic Scale, version 1.2; CPMS, Childhood Psychopathology Measurement Schedule; CSI-4, Children’s Symptom Inventory (CSI-4)-Parent Form; SDAG, The parent version of the ADHD rating scale (Scala per i Disturbi di Attenzione/Iperattività per Insegnanti or SDAG); DIVA, Diagnostic Interview for ADHD in Adults; DBD, Disruptive Behavior Disorder Rating Scale; Raven’s SPM, Raven’s progressive matrices test for estimation of intellectual functioning and observation for their behavior in the classrooms by one researcher; CGAS, Children’s Global Assessment Score, SDI, The Children’s Depression Inventory; SDAI, Rating Scale (ADHD Rating Scale for Teachers [Scala per i Disturbi di Attenzione/Iperattività per Insegnanti]; SNAP-IV, The Swanson, Nolan and Pelham Scale-Version IV; DDE, Battery for Evaluating Dyslexia and Dysorthography; M.T. reading test, a text, varying for each grade and phase of the scholastic year (initial, middle and final), that the participants are asked to read; K-CBCL, Korean Child Behavior Checklist; CPRS-R:S, The Conners’ parent rating scale - Revised, the Spanish version; CPRS, The Conners’ parent rating scale; CPRS-R, The Conners’ parent rating scale - Revised; ECI-4, The Early Childhood Inventory-4; K-SADS Schedule for Affective Disorders and Schizophrenia for School-Aged Children (Epidemiological version); T-DSM-IV-S, The Turgay DSM-IV Disruptive Behavior Disorders Rating Scale; WISC-R, The Wechsler Intelligence Scale for Children-Revised; CAPA, The Child and Adolescent Psychiatric Assessment; DIS, Diagnostic Interview Schedule; ACDS, The Adult ADHD; NTRS, The NIEHS Teacher Rating Scale; DISC, Diagnostic Interview Schedule for Children; CTRS-R, the Conners teacher rating scale - Revised; MINI Kid, Mini International Neuropsychiatric Interview for Children and Adolescents; SNAP-IVP/T-S, The validated and pretested Sinhala version of SNAP-IV Parent and Teacher rating scale; SAQ, The self-administered questionnaire; IAQ, interviewer administered questionnaire.
Two studies were conducted in North America, 4 in South America, 13 in Europe, 16 in Asia, 8 in Africa, and 6 in the Middle East. The prevalence of ADHD in children and/or adolescents was assessed in a great proportion of the studies included in this review. In five studies, the prevalence of ADHD in adults was assessed. In the study of Michielsen et al. [Reference Michielsen, Semeijn, Comijs, van de Ven, Beekman and Deeg120], the estimated prevalence rate of syndromic ADHD in older adults was 2.8%; for symptomatic ADHD, the rate was 4.2%. Younger elderly adults (60–70 years) reported significantly more ADHD symptoms than older elderly adults (71–94 years) [Reference Michielsen, Semeijn, Comijs, van de Ven, Beekman and Deeg120]. Fayyad et al. [Reference Fayyad, Sampson, Hwang, Adamowski, Aguilar-Gaxiola and Al-Hamzawi23] assessed ADHD prevalence in adult respondents aged 18–44 years in 10 countries in the Americas, Europe, and the Middle East. Estimates of ADHD prevalence averaged 3.4% (range 1.2–7.3%), with a lower prevalence in lower-income countries (1.9%) compared with higher-income countries (4.2%) [Reference Fayyad, Sampson, Hwang, Adamowski, Aguilar-Gaxiola and Al-Hamzawi23]. However, masked clinical reappraisal interviews administered to 154 US respondents in this study yielded a prevalence estimate of 5.2% for adult ADHD [Reference Fayyad, Sampson, Hwang, Adamowski, Aguilar-Gaxiola and Al-Hamzawi23]. In the study of Matte et al. [Reference Matte, Anselmi, Salum, Kieling, Gonçalves and Menezes119], ADHD prevalence in 18- to 19-year-old young adults was assessed. The prevalence of DSM-5 ADHD was 3.55% [95% confidence interval (CI) 2.98–4.12], and the estimated prevalence of DSM-IV ADHD was 2.8% [Reference Matte, Anselmi, Salum, Kieling, Gonçalves and Menezes119]. Urban inhabitants of Tabriz (Iran) aged 18–45 years were selected for the study of Amiri et al. [Reference Amiri, Ghoreishizadeh, Sadeghi-Bazargani, Jonggoo, Golmirzaei and Abdi94], and the prevalence of adult ADHD was estimated to be 3.8%. Men, when compared with women, were more likely to have ADHD (5.5% in men versus 2% in women) [Reference Amiri, Ghoreishizadeh, Sadeghi-Bazargani, Jonggoo, Golmirzaei and Abdi94]. Kessler et al. [Reference Huang, Zheng, Xu, Lin, Wu, Zheng, Zhang and Xu113] evaluated adult ADHD in a probability subsample of 18- to 44-year-old respondents in the National Comorbidity Survey Replication. The estimated prevalence of current adult ADHD was 4.4% [Reference Huang, Zheng, Xu, Lin, Wu, Zheng, Zhang and Xu113]. The Diagnostic criteria used in two-stage clinical studies were preferably DSM criteria; ADHD prevalence ranged between 0.6% in the study by Puura et al. [Reference Puura, Almqvist, Tamminen, Piha, Räsänen and Kumpulainen128] and 16.4% in the study by Pineda et al. [Reference Pineda, Lopera, Palacio, Ramirez and Henao127]. Heiervang et al. [Reference Heiervang, Stormark, Lundervold, Heimann, Goodman and Posserud112] used both the DSM and ICD criteria. Bansal et al. [Reference Bansal and Barman95], Elberling et al. [Reference Elberling, Linneberg, Rask, Houman, Goodman and Mette Skovgaard107], and Deivasigamani et al. [Reference Deivasigamani104] used the ICD criteria, and the prevalence rates of kinetic syndrome/disorder were 6%, 1%, and 1.7%.
In two-stage clinical studies, the DSM diagnostic criteria were preferably used. Only in the studies of Bansal et al. [Reference Bansal and Barman95], Elberling et al. [Reference Elberling, Linneberg, Rask, Houman, Goodman and Mette Skovgaard107], and Deivasigamani et al. [Reference Deivasigamani104], the ICD diagnostic criteria were used.
Meta-analysis
In the meta-analysis, we analyzed separately each type of studies (register and survey studies, one-stage and two-stage clinical studies). Age categories were used as subgroups. Results are presented in Figure 2.
Summary of the meta-analysis results. Points with error bars represent the overall prevalence with 95% confidence intervals of each age subgroup (i.e., the diamond in a forest plot). Full forest plots are presented in the Supplementary material. Numbers in brackets represent the number of independent datapoints included in each age category.
Studies were grouped in according to age. In the case of less than three studies in the subgroup, these studies were excluded. We identified 103 eligible studies for meta-analysis.
One-stage clinical studies
We analyzed 28 independent datapoints (in total 22 studies). The overall prevalence of ADHD in one-stage clinical studies was 4.2%, 95% CI [2.9; 6.0]. In age subgroups, the results were 4.9%, 95% CI [2.6; 9.0] for school children; 3.7%, 95% CI [1.8; 7.4] for adolescents, and 4.1%, 95% CI [1.7; 9.5] for school children and adolescents.
Two-stage clinical studies
We analyzed 79 independent datapoints (in total 49 studies). The overall prevalence of ADHD in two-stage clinical studies was 4.8%, 95% CI [4.0; 5.8]. In age subgroups, the results were 5.5%, 95% CI [2.9; 10.1] for preschool children; 6.1%, 95% CI [4.9; 7.5] for school children, 4.6%, 95% CI [2.8; 7.3] for school children and adolescents, 3.1%, 95% CI [1.6; 5.8] for adolescents, and 3.3%, 95% CI [1.9; 5.9] for adults.
Survey studies
We analyzed 14 independent datapoints (in total 8 studies). The overall prevalence of ADHD in survey studies was 5.0%, 95% CI [2.9; 8.6]. In age subgroups, the results were 1.4%, 95% CI [0.6; 3.3] for preschool children; 8.5%, 95% CI [7.9; 9.2] for preschool and school children and adolescents; 6.4%, 95% CI [2.1; 18.0] for school children and 11.1%, 95% CI [9.1; 13.5] for adolescents.
Register studies
We analyzed 38 independent datapoints (in total 24 studies). The overall prevalence of ADHD in register studies was 1.6%, 95% CI [0.9; 3.0]. In age subgroups, the results were 0.3%, 95% CI [0.0; 3.8] for preschool children; 4.2%, 95% CI [1.8; 9.4] for school children, 3.5%, 95% CI [1.9; 6.4] for preschool and school children and adolescents; 5.1%, 95% CI [1.9; 12.8] for school children and adolescents;4.1%, 95% CI [0.9; 16.7] for adolescents; 0.2%, 95% CI [0.0; 2.1] for adults; and 0.9%, 95% CI [0.3; 2.7] for all ages.
Discussion
We conducted a comprehensive systematic review of studies evaluating worldwide prevalence rates of ADHD to understand better and explain the variability in ADHD prevalence data. The prevalence of ADHD was investigated across different age categories (children, adolescents, and adults). We compared the results among the different types of studies (register and survey studies, one-stage and two-stage clinical studies). These data must be interpreted cautiously due to the high variability in the analyses that are conducted. The results of this systematic review show that the overall prevalence of ADHD in register studies was 1.6%, 95% CI [0.9; 3.0], in survey studies was 5.0%, 95% CI [2.9; 8.6], in one-stage clinical studies was 4.2%, 95% CI [2.9; 6.0], and in two-stage clinical studies was 4.8%, 95% CI [4.0; 5.8]. The register studies exhibit the lowest estimate for ADHD prevalence, mostly because of inclusion of the entire population (e.g., children under 2 years old), while the other three types of studies show similar estimates. However, our results also indicate that the type of study methodology significantly impacts the estimation of ADHD prevalence. Register-based studies depend on the quality of different data collections (input data). Since ADHD still lacks biological markers, diagnosis relies on physicians’ education and practice [Reference Davidovitch, Koren, Fund, Shrem and Porath34], and cultural factors may also play a significant role in the identification of ADHD [Reference Alhraiwil, Ali, Househ, Al-Shehri and El-Metwally11]. Therefore, ADHD prevalence can vary significantly. One-stage and two-stage clinical studies provide more comparable ADHD prevalence data.
Most of the studies included in our review utilized the DSM and/or ICD diagnostic criteria to diagnose ADHD. Additionally, different data collection tools, such as the DSM/ICD questionnaire, K-SADS, MINI, DAWBA, and DISC, were used in the included one-stage and two-stage clinical studies. When the diagnosis was based on DSM criteria, the edition of criteria affected the median prevalence in one-stage and two-stage clinical studies (lower average of prevalence medians in DSM-III vs. DSM-IV or DSM-5 criteria). However, the number of studies using the DSM-III criteria was significantly lower than those using updated diagnostic criteria.
Additional variations in the prevalence estimates can be attributed to the study populations. The prevalence of ADHD varies with age [Reference Hakim Shooshtari, Shariati, Kamalzadeh, Naserbakht, Tayefi and Taban9]. Previous systematic reviews have shown lower ADHD prevalence in adults compared to school children and adolescents [Reference Polanczyk, Salum, Sugaya, Caye and Rohde3, Reference Ayano, Yohannes and Abraha12, Reference Thomas, Sanders, Doust, Beller and Glasziou17–Reference Song, Zha, Yang, Zhang, Li and Rudan22]. Most of the studies in our review have been performed on children and adolescents. It is important to note that psychiatric diseases often persist into adulthood, leading to individual and collective social and economic burdens [Reference Barican, Yung, Schwartz, Zheng, Georgiades and Waddell1]. The differences in prevalence estimates between children and adults can be attributed to delayed brain maturation [Reference Kakuszi, Szuromi, Bitter and Czobor139]. This delayed maturation, particularly in the frontal areas, may lead to a protracted developmental trajectory in ADHD, with brain function normalizing in young adulthood but declining prematurely in later years. Consequently, the neurobiological changes observed in ADHD during adulthood may contribute to the varying prevalence rates seen across different age groups [Reference Kakuszi, Szuromi, Bitter and Czobor139].
Our study must be considered in the context of its limitations. First, several methodological issues need to be addressed. We limited our search to articles published in English for this review, while articles in other languages were not considered. Although most studies are published in English, we may have missed some articles (mainly in Chinese). Additionally, our search was limited to PubMed®, which may result in fewer articles being included. To address these limitations, replicating our systematic review, including other databases, such as Embase, is recommended. We also included only studies that included the general population, which might underrepresent local situations and represent the limitation of the evidence. Excluding other populations (e.g., institutionalized populations, “special needs” children) can lead to an underestimation of the actual burden of ADHD, which is necessary data for disease burden calculations. Second, we analyzed studies conducted at different time points and locations; this issue could be examined in a proper meta-regression analysis. Although we compared studies by type, not all methods used were standardized. Third, the number of studies was not evenly distributed in all geographical locations, especially in Africa, Oceania, and the Middle East. Additional studies in these regions are needed to confirm our results, calling for a meta-regression analysis in this area.
Despite some limitations, the results of our study have important implications. First, we included studies with clinically confirmed diagnoses of ADHD, which may contribute to the more objective and precise ADHD prevalence data compared to the systematic reviews that also included studies where ADHD diagnosis was based on nonclinical questionnaire results. Second, the type of study (methodology) significantly affects the estimation of ADHD prevalence. It is necessary to standardize diagnostic procedures to monitor the rates of ADHD efficiently. Third, our results can assist policymakers in better understanding ADHD, which is essential for resource planning and implementing global strategies for ADHD management worldwide. Our results can also encourage researchers to conduct additional analyses and systematic reviews, incorporating more databases.
In conclusion, the results from this systematic review and meta-analysis suggest that the type of study significantly affects the prevalence of ADHD. Standard diagnostic procedures to estimate ADHD prevalence may contribute to accurate prevalence data and provide high-quality, relevant, accessible, and up-to-date information for policymakers. Based on these findings, we propose that the current estimate of prevalence of ADHD should be based on the average of all study types.
Supplementary material
The supplementary material for this article can be found at http://doi.org/10.1192/j.eurpsy.2024.1786.
Data availability statement
For supplementary material accompanying this article, visit cambridge.org/EPA.
Acknowledgments
The authors would like to thank Nana Turk, librarian at the Central Medical Library, Faculty of Medicine, University of Ljubljana, Slovenia, who assisted them in optimizing the search strategy for the electronic databases search.
Financial support
The authors declare that financial support was received for the research, authorship, and/or publication of this article (financial support from the Slovenian Research and Innovation Agency, research core funding No. J3-50127 and research funding No. P1-0189).
Competing interest
The authors declare none. The authors are solely responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.
Open access
Comments
No Comments have been published for this article.